Neurovance, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2009)
Status: Acquired by Otsuka (2017)

Organization Overview

First Clinical Trial
2013
NCT01744808
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

centanafadine (5 trials)

Drugs in Phase 1 Trials (2)

amphetamine (Adderall) (1 trial)

lisdexamfetamine (vyvanse) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Attention Deficit Disorder with Hyperactivity (Phase 2)

Hyperkinesis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 3